Pain News and Research RSS Feed - Pain News and Research

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). [More]
Longer looks: the economics of infertility; placebos as treatment raises ethical dilemmas

Longer looks: the economics of infertility; placebos as treatment raises ethical dilemmas

About a decade ago, Medicaid programs were struggling to keep up with skyrocketing prescription drug costs. Between 1997 and 2002, drug spending in the program for low-income Americans grew by about 20 percent annually. ... Medicaid directors began looking for ways to tamp down on those costs. One of the most popular policies was something called "prior authorization" for a new wave of more expensive, anti-psychotic drugs ,... These policies, in a sense, worked: they helped rein in how much Medicaid spent filling prescriptions. But in another sense, they may not have worked at all: a growing body of research has begun questioning whether restricting drug spending may have just shifted costs elsewhere -; particularly, into the prison system (Sarah Kliff, 7/22). [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]
Highlights: Texas abortion rates falls dramatically; start-up problems for Virginia's psychiatric reforms

Highlights: Texas abortion rates falls dramatically; start-up problems for Virginia's psychiatric reforms

A four-month-old psychiatric-bed registry that is supposed to provide up-to-the-minute information for Virginians who need emergency mental health treatment is being updated as seldom as once a day, state officials told a panel of lawmakers this week (Shin, 7/22). [More]
Paracetamol fails to beat placebo at relieving back pain

Paracetamol fails to beat placebo at relieving back pain

Paracetamol is no more effective than placebo at relieving acute lower back pain, according to new clinical trial results. [More]
Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc., announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties. [More]
Brown recluse spider bites increases this summer, say toxicologists

Brown recluse spider bites increases this summer, say toxicologists

Vanderbilt medical toxicologists are reporting an increase in patients seen with brown recluse spider bites this summer. [More]
Research suggests effective role for natural steroid hormones in treating breast cancer

Research suggests effective role for natural steroid hormones in treating breast cancer

A new study supports a growing body of research suggesting a safe and effective role for natural steroid hormones in treating postmenopausal breast cancer, with fewer detrimental side effects and improved health profile than with standard anti-hormone therapies. [More]

National Pain Week: NPS MedicineWise advises people on how to manage pain

This National Pain Week (21 – 27 July 2014), NPS MedicineWise is urging people living with pain to know how to use pain relieving medicines safely, and to have a conversation with their health professional about both the type and dose of pain relief medicine that are right for them. [More]

EndoControl wins 'World Innovation Challenge' award for ARCC project

EndoControl, a leading innovator of robot-assisted systems for endoscopic surgery, today announces that its CEO Clement Vidal has won an award in the 'World Innovation Challenge' for his ARCC project (Robot-assisted Co-Manipulation in Surgery) in the 'personalized medicine' category. [More]
Increased number of Americans infected with chikungunya, say researchers

Increased number of Americans infected with chikungunya, say researchers

In just two weeks, the number of Americans infected with the mosquito-borne virus chikungunya has almost doubled and the virus has now been found in mosquitoes in the United States, something that is very concerning to a Kansas State University professor who is a leading researcher of the virus. [More]
FDA approves Targiniq ER to treat severe pain

FDA approves Targiniq ER to treat severe pain

Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. [More]
Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found. [More]
Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. [More]
Experts join together to call for better screening of psoriatic arthritis

Experts join together to call for better screening of psoriatic arthritis

Leading experts have joined together for the first time to call for better screening of psoriatic arthritis to help millions of people worldwide suffering from the condition. [More]
Scientist develops highly accurate device for diagnosing fatal lung disease

Scientist develops highly accurate device for diagnosing fatal lung disease

A scientist from the University of Exeter has developed a simple, cheap and highly accurate device for diagnosing a frequently fatal lung disease which attacks immune deficient individuals such as cancer patients and bone marrow transplant recipients. [More]
Severe pain during and post delivery linked to postpartum depression

Severe pain during and post delivery linked to postpartum depression

Controlling pain during childbirth and post delivery may reduce the risk of postpartum depression, writes Katherine Wisner, M.D., a Northwestern Medicine- perinatal psychiatrist, in a July 23 editorial in Anesthesia & Analgesia. [More]
Immunosignaturing holds promise for accurate diagnosis of Valley Fever

Immunosignaturing holds promise for accurate diagnosis of Valley Fever

On July 5, 2011, a massive wall of dust, ("haboob," in Arabic), blanketed Phoenix, Arizona, creating an awesome spectacle, (or stubborn nuisance, depending on your perspective). Dust storms are a common occurrence in the arid desert environments of the American Southwest. [More]
Highlights: Florida officials crack down on direct Medicaid marketing; a wellness plan in Washington state breaks the mold

Highlights: Florida officials crack down on direct Medicaid marketing; a wellness plan in Washington state breaks the mold

[Florida] health officials are taking a cue from past problems and are banning health insurance companies from marketing their plans directly to Medicaid consumers as the state is rolling out a massive overhaul by transitioning millions into managed care. Insurance companies are allowed to market to consumers under the contracts, but only if the state gives prior approval (Kennedy, 7/22). [More]
Activity level predicts how well patients recover from injuries after treatment

Activity level predicts how well patients recover from injuries after treatment

According to a literature review in the July issue of the Journal of the American Academy of Orthopaedic Surgeons, patients' activity level is a strong predictor for how well they will do with certain treatments and how well they recover from injuries after treatment. Patients are encouraged to ask their orthopaedic surgeon if activity level is an important factor in their treatment decision. [More]